Journal
GYNECOLOGICAL ENDOCRINOLOGY
Volume 36, Issue 10, Pages 860-863Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/09513590.2020.1744556
Keywords
AI (aromatase inhibitor); polycystic ovary syndrome (PCOS); letrozole; insulin resistance; IUI (intrauterine insemination)
Funding
- Mililary Institute of Clinical Embryogly and Histology, Military Medical University
Ask authors/readers for more resources
Objectives: To evaluate the efficacy and safety of letrozole on ovulation induction and pregnancy in infertility patients with polycystic ovary syndrome (PCOS). In addition, the insulin resistance was analyzed in these patients. Subjects and methods: Progressive description study with comparison. The study included 80 infertility women divided into two groups: 40 women with PCOS (the study group) and 40 women without PCOS (the control group). The both used letrozole for ovulation induction from cycle day 2. Results: No differences in the dominant follicle between the study group and the control group (1.16 +/- 0.37 follicles and 1.30 +/- 0.46 follicles, respectively). The clinical pregnancy rate was 22.5% of the both groups. The average insulin of the study group (10.85 +/- 5.84 mu UI/ml) and their average HOMA-IR (2.42 +/- 1.34) were higher than the control group (7.44 +/- 2.84 mu UI/ml and 1.57 +/- 0.68), p < .05. The QUICKI of the study group (0.35 +/- 0.29) was lower than the control group (0.36 +/- 0.25), p < .05. Conclusion: Letrozole is used to stimulate the ovaries of the infertile women with PCOS combined with intrauterine insemination is the effective treatment. These patients had the high risk of insulin resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available